Search Results - "Pro, B"

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma by Horwitz, S., O'Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Zinzani, P.L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.

“…For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)…”
Get full text

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial by Wang, M, Fowler, N, Wagner-Bartak, N, Feng, L, Romaguera, J, Neelapu, S S, Hagemeister, F, Fanale, M, Oki, Y, Pro, B, Shah, J, Thomas, S, Younes, A, Hosing, C, Zhang, L, Newberry, K J, Desai, M, Cheng, N, Badillo, M, Bejarano, M, Chen, Y, Young, K H, Champlin, R, Kwak, L, Fayad, L

“…Lenalidomide–rituximab therapy is effective in grade 1–2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL),…”
Get full text

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome by Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemeister, F.B., Bueso-Ramos, C.E., Zhou, X., McLaughlin, P.W., Fowler, N., Shah, J., Orlowski, R.Z., Samaniego, F., Wang, M., Cortes, J.E., Younes, A., Kwak, L.W., Sarlis, N.J., Romaguera, J.E.

“…Tumor lysis syndrome (TLS) is a life-threatening disorder characterized by hyperuricemia and metabolic derangements. The efficacy of rasburicase, administered…”
Get full text

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment by Falchook, G. S., Vega, F., Dang, N. H., Samaniego, F., Rodriguez, M. A., Champlin, R. E., Hosing, C., Verstovsek, S., Pro, B.

“…Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens…”
Get full text

Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL by Tolu, S. S., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A., Shore, T., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., Ruan, J.

Get full text

Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology by Mehta‐Shah, N., Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter‐Brown, L., Izutsu, K., Waters, S., Brammer, J. E., Pro, B., Horwitz, S. M.

Get full text

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA by Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., Piekarz, R.

Get full text

MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL) by Ruan, J., Zain, J. M, Palmer, B., Jovanovic, B. Borko, Mi, X., Swaroop, A., Winter, J., Gordon, L. I, Karmali, R., Pro, B.

Get full text

CD26/dipeptidyl peptidase IV and its role in cancer by Pro, B, Dang, N H

“…CD26/Dipeptidyl Peptidase IV (DPPIV) is a 110-kDa glycoprotein that is expressed on numerous cell types and has multiple biological functions. A key facet of…”
Get full text

Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma by Horwitz, S. M., Coiffier, Bertrand, Foss, F, Prince, H. M., Sokol, L, Greenwood, M, Caballero, Dolores, Morschhauser, Franck, Pinter-Brown, L, Iyer, S. P., Shustov, A, Nichols, J, Balser, J, Balser, B., Pro, B

“…BACKGROUND: For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for…”
Get full text

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma by Esmaeli, B., McLaughlin, P., Pro, B., Samaniego, F., Gayed, I., Hagemeister, F., Romaguera, J., Cabanillas, F., Neelapu, S. S., Banay, R., Fayad, L., Wayne Saville, M., Kwak, L. W.

“…Background: To determine the efficacy and side-effects of 90Y ibritumomab tiuxetan (Zevalin) as front-line treatment in patients with early-stage extranodal…”
Get full text

Current management of peripheral T-cell lymphomas by Gooptu, M, Rhoades, R, Pro, B

“…Peripheral T-cell lymphomas (PTCLs) are an uncommon group of lymphoproliferative disorders accounting for approximately 10-15 % of all non-Hodgkin lymphomas…”
Get more information

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31) by Conconi, A., Vannata, B., Janikova, A., Ramirez, A., Bodoni, C. Lobetti, Nowakowski, G., Mian, M., Ferreri, Andrés J.M., Ryan, G., Pangalis, G. A., Cabrera, M. E., Luminari, S., Montoto, S., Tsang, R., Aurer, I., Visco, C., Mazzucchelli, L., Trneny, M., Gaidano, G., Federico, M., Lopez‐Guillermo, A., Pro, B., Zucca, E.

Get full text

TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T‐CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST‐HOC ANALYSIS OF THE MAVORIC STUDY by Kim, Y.H., Ortiz‐Romero, P.L., Pro, B., Sokol, L., Scarisbrick, J., Musiek, A., Vermeer, M., Dummer, R., Halwani, A., Fierro, M., Moriya, J., Leoni, M., Bagot, M.

Get full text

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience by Anderlini, Paolo, Saliba, Rima, Acholonu, Sandra, Giralt, Sergio A, Andersson, Borje, Ueno, Naoto T, Hosing, Chitra, Khouri, Issa F, Couriel, Daniel, de Lima, Marcos, Qazilbash, Muzaffar H, Pro, Barbara, Romaguera, Jorge, Fayad, Luis, Hagemeister, Frederick, Younes, Anas, Munsell, Mark F, Champlin, Richard E

“…1 Department of Stem Cell Transplantation and Cellular Therapy; 2 Lymphoma and 3 Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston,…”
Get full text

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS by Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Jacobsen, E. D., Gritti, G., Pinter‐Brown, L., Isutzu, K., Cohan, D., Daugherty, M., Brammer, J. E., Mehta‐Shah, N., Pro, B., Horwitz, S. M.

Get full text

Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma by Horwitz, S, Coiffier, B, Foss, F, Prince, H M, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Pinter-Brown, L, Iyer, S P, Shustov, A, Nichols, J, Balser, J, Balser, B, Pro, B

“…For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis…”
Get full text

GSK‐3ß INHIBITOR, 9‐ING‐41 REDUCES CELL VIABILITY AND HALTS PROLIFERATION OF B‐CELL LYMPHOMA by Karmali, R., Chukkapalli, V., Pro, B., Borgia, J.A., Mazar, A., Ugolkov, A., Giles, F.J.

Get full text

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen by ANDERLINI, P, SALIBA, R, HOSING, C, COHEN, A, IPPOLITI, C, ROMAGUERA, J, RODRIGUEZ, M. A, PRO, B, FAYAD, L, GOY, A, YOUNES, A, CHAMPLIN, R. E, ACHOLONU, S, OKOROJI, G.-J, DONATO, M, GIRALT, S, ANDERSSON, B, UENO, N. T, KHOURI, I, DE LIMA, M

“…A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation…”
Get full text

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma by Overman, M.J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J.E., Hagemeister, F.B., Kwak, L., Cabanillas, F., Rodriguez, M.A., Fayad, L.E.

“…The benefit of adding rituximab to anthracycline-based therapy for follicular lymphoma grade 3 has not been studied. We retrospectively reviewed the records of…”
Get full text